A Phase 3 interventional study of olaparib and durvalumab in Endometrial Neoplasms, sponsored by AstraZeneca. Active, not recruiting at 201 sites in 22 countries. Open to female participants aged 18 Years to 150 Years. Per ClinicalTrials.gov, last updated 2026-11-05.
Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing olaparib in Endometrial Neoplasms — 3 open to participants now, 6 under way, 3 of them phase 3. olaparib · Endometrial Neoplasms.
Among the 11 studies testing olaparib in Endometrial Neoplasms, this one is the 2nd largest by enrollment, is the only one that started in 2020, is one of 3 in phase 3, and was the 5th registered.
1,428 studies on the registry are indexed under Endometrial Neoplasms; 472 are open to participants now.
Browse Endometrial Neoplasms studies →3 of the 11 studies testing olaparib in Endometrial Neoplasms are open now, in 4 countries. Recruiting first, the newest first:
Gustave Roussy, Cancer Campus, Grand Paris · Sites in France
Ages 18+ · Women only
National Cancer Institute (NCI) · Sites in United States, Puerto Rico
University Medical Center Groningen · Sites in Netherlands
Ages 65+
By country, each count listing its studies:
olaparib: first FDA approval 2014 (LYNPARZA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 356 Endometrial Neoplasms studies recruiting now, 266 (75%) set no upper age limit and 54 (15%) stop at 75 or younger; 26 take children under 18; 23 take healthy volunteers.
This study: 18 Years to 150 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, olaparib is the treatment under test here. Read study by study →
11 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 5 · Phase 3 3 · Phase 4 1
First in 2011; this study’s year is marked. 1 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 805 is above the median of 71 across 1,029 interventional studies indexed under Endometrial Neoplasms.
Median enrollment 77 across the 11 interventional studies. Of the 4 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 11 have an industry lead sponsor. The 8 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
17 studies in Endometrial Neoplasms by AstraZeneca: 9 open now, 13 under way, 4 of them phase 3. Of 4 finished, 1 (25%) have results posted.
Among the 17 studies in Endometrial Neoplasms by AstraZeneca, this one has the largest enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2020, is one of 4 in phase 3, reaches primary completion later than 0 of the 12 other live ones, and was the 4th registered.
AstraZeneca’s Endometrial Neoplasms studies by the year they started, since 2002.
None of the studies under way reaches primary completion within a year.
Among the 11 studies testing olaparib in Endometrial Neoplasms, from their registry updates:
Among AstraZeneca’s 17 in Endometrial Neoplasms:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
A study to assess the efficacy and safety of durvalumab in combination with platinum-based chemotherapy (paclitaxel + carboplatin) followed by maintenance durvalumab with or without olaparib for patients with newly diagnosed advanced or recurrent endometrial cancer.
This Phase III study will assess the efficacy and safety of durvalumab in combination with platinum-based chemotherapy (paclitaxel + carboplatin) followed by maintenance durvalumab with or without olaparib for patients with newly diagnosed advanced or recurrent endometrial cancer.
Target patient population: Adult female patients with histologically confirmed diagnosis of epithelial endometrial carcinoma (excluding sarcomas): newly diagnosed Stage III, newly diagnosed Stage IV, or recurrent endometrial cancer
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patient must have endometrial cancer in one of the following categories:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platinum-based chemotherapy and durvalumab placebo followed by maintenance durvalumab placebo and olaparib placebo (tablets).
Drug: durvalumab placebo · Drug: olaparib placebo · Drug: Carboplatin · Drug: Paclitaxel
Platinum-based chemotherapy and durvalumab followed by maintenance durvalumab and olaparib placebo
Biological: durvalumab · Drug: olaparib placebo · Drug: Carboplatin · Drug: Paclitaxel
Platinum-based chemotherapy and durvalumab followed by maintenance durvalumab and olaparib.
Drug: olaparib · Biological: durvalumab · Drug: Carboplatin · Drug: Paclitaxel
Olaparib tablets
Durvalumab by intravenous infusion
Matching placebo for intravenous infusion
Placebo tablets to match olaparib
Standard of care chemotherapy
Standard of care chemotherapy
Progression-free Survival (PFS) According to RECIST 1.1, Based on Investigator Assessments
To demonstrate the efficacy of durvalumab in combination with platinum-based chemotherapy (paclitaxel and carboplatin) followed by maintenance durvalumab or durvalumab with olaparib when compared to platinum-based chemotherapy by assessment of PFS (using investigator assessment according to Response Evaluation Criteria in Solid Tumours version 1.1 \[RECIST 1.1\]) in patients with newly diagnosed advanced or recurrent endometrial cancer
Time frame: At baseline, every 9 weeks (wks) up to 18 wks, then every 12 wks until objective radiological disease progression. Assessed until 12 Apr 2023 DCO (08 Jul 2024 DCO for China cohort), up to 50 months
Overall Survival (OS) Analysis
To determine the efficacy of durvalumab in combination with platinum-based chemotherapy (paclitaxel and carboplatin) followed by maintenance durvalumab or durvalumab with olaparib when compared to platinum-based chemotherapy in newly diagnosed advanced or recurrent endometrial cancer patients by assessment of OS
Time frame: Survival assessed every 2 months after RECIST defined radiological progression; assessed through study completion, up to 83 months
Time From Randomisation to Second Progression or Death (PFS2) Based on Local Standard Clinical Practice
To determine the efficacy of durvalumab in combination with platinum-based chemotherapy (paclitaxel and carboplatin) followed by maintenance durvalumab or durvalumab with olaparib when compared to platinum-based chemotherapy in newly diagnosed advanced or recurrent endometrial cancer patients by assessment of PFS2
Time frame: At baseline, every 9 to 18 wks, then every 12 wks until objective radiological disease progression. Assessments then per local practice every 12 wks until second progression. Assessed until 12Apr2023 DCO (08Jul2024 DCO for China cohort), up to 50 months
Objective Response Rate (ORR) Based on Investigator Assessment
To determine the efficacy of durvalumab in combination with platinum-based chemotherapy (paclitaxel and carboplatin) followed by maintenance durvalumab or durvalumab with olaparib when compared to platinum-based chemotherapy in newly diagnosed advanced or recurrent endometrial cancer patients by assessment of ORR
Time frame: At baseline, every 9 to 18 wks, then every 12 wks until objective radiological disease progression. Assessed until 12 Apr 2023 DCO (08 Jul 2024 DCO for China cohort), up to 50 months
Duration of Response (DoR) Based on Investigator Assessment
To determine the efficacy of durvalumab in combination with platinum-based chemotherapy (paclitaxel and carboplatin) followed by maintenance durvalumab or durvalumab with olaparib when compared to platinum-based chemotherapy in newly diagnosed advanced or recurrent endometrial cancer patients by assessment of DoR
Time frame: At baseline, every 9 wks up to 18 wks, then every 12 wks until objective radiological disease progression. Assessed until 12 Apr 2023 DCO, up to 35 months
Time From Randomisation to First Subsequent Therapy or Death (TFST)
To determine the efficacy of durvalumab in combination with platinum-based chemotherapy (paclitaxel and carboplatin) followed by maintenance durvalumab or durvalumab with olaparib when compared to platinum-based chemotherapy in newly diagnosed advanced or recurrent endometrial cancer patients by assessment of TFST
Time frame: Time elapsed from randomisation to first subsequent therapy or death. Assessed every 12 wks following treatment discontinuation, through study completion (up to 83 months)
Time From Randomisation to Second Subsequent Therapy or Death (TSST)
To determine the efficacy of durvalumab in combination with platinum-based chemotherapy (paclitaxel and carboplatin) followed by maintenance durvalumab or durvalumab with olaparib when compared to platinum-based chemotherapy in newly diagnosed advanced or recurrent endometrial cancer patients by assessment of TSST
Time frame: Time elapsed from randomisation to second subsequent therapy or death. Assessed every 12 wks following treatment discontinuation, through study completion (up to 83 months)
Time From Randomisation to Discontinuation of Treatment or Death (TDT)
To determine the efficacy of durvalumab in combination with platinum-based chemotherapy (paclitaxel and carboplatin) followed by maintenance durvalumab or durvalumab with olaparib when compared to platinum-based chemotherapy in newly diagnosed advanced or recurrent endometrial cancer patients by assessment of TDT
Time frame: Time elapsed from randomisation to study treatment discontinuation or death. Assessed through study completion, up to 83 months
Serum Concentration of Durvalumab
To characterise the pharmacokinetics (PK) of durvalumab and durvalumab in combination with olaparib
Time frame: PK sampling performed on Day 85 pre-dose, Day 183 pre-dose, and 3 months after study treatment discontinuation (up to 36 months)
Anti-drug Antibodies (ADA) to Durvalumab
To characterise the immunogenicity of durvalumab and durvalumab in combination with olaparib
Time frame: Immunogenicity sampling performed on Day 1 pre-dose, Day 85 pre-dose, Day 183 pre-dose, and 3 and 6 months after study treatment discontinuation (up to 39 months)
Change From Baseline in Physical Functioning Score of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire for Cancer Patients 30 (EORTC QLQ-C30)
To determine effects on symptoms, functioning, and overall health related quality of life (HRQoL) of durvalumab in combination with platinum-based chemotherapy (paclitaxel and carboplatin) followed by maintenance durvalumab or durvalumab with olaparib when compared to platinum-based chemotherapy alone in newly diagnosed advanced or recurrent endometrial cancer patients. The physical functioning score is a score from 0 to 100. Higher scores on the physical functioning score indicate better health status/function.
Time frame: At baseline, every 3 wks until Wk 18, and every 4 wks until the second progression. Assessed until 12 Apr 2023 DCO, up to 35 months. The average treatment effect over the first 12 months after randomisation is presented.
Change From Baseline in Global Health Status/QoL Score of the EORTC QLQ-C30
To determine effects on symptoms, functioning, and overall HRQoL of durvalumab in combination with platinum-based chemotherapy (paclitaxel and carboplatin) followed by maintenance durvalumab or durvalumab with olaparib when compared to platinum-based chemotherapy alone in newly diagnosed advanced or recurrent endometrial cancer patients. The global health status/quality of life (QoL) is a score from 0 to 100. Higher scores on the global health status/QoL indicate better health status/function.
Time frame: At baseline, every 3 wks until Wk 18, and every 4 wks until the second progression. Assessed until 12 Apr 2023 DCO, up to 35 months. The average treatment effect over the first 12 months after randomisation is presented.
Global Cohort: 875 patients screened across 179 centres in 22 countries; 718 were randomised. Results were reported for analysis of progression-free survival (PFS) (data cut-off \[DCO\]: 12 Apr 2023). China Cohort: 172 patients screened across 25 sites; 129 were randomized. Results were reported for analysis of PFS (DCO: 08 Jul 2024). In total, 805 patients were randomised; 718 to the Global cohort, 129 to the China cohort, with 42 patients overlapping and belonging to both cohorts.
| Milestone | Standard of Care (SoC) | SoC + Durvalumab | SoC + Durvalumab + Olaparib |
|---|---|---|---|
| Started | 241 | 238 | 239 |
| Completed | 147 | 159 | 170 |
| Not completed | 94 | 79 | 69 |
| Withdrew: Death | 72 | 54 | 49 |
| Withdrew: Lost to follow-up | 0 | 0 | 2 |
| Withdrew: Withdrawal by subject | 22 | 25 | 18 |
| Milestone | Standard of Care (SoC) | SoC + Durvalumab | SoC + Durvalumab + Olaparib |
|---|---|---|---|
| Started | 44 | 43 | 42 |
| Completed | 30 | 29 | 24 |
| Not completed | 14 | 14 | 18 |
| Withdrew: Death | 12 | 11 | 13 |
| Withdrew: Lost to follow-up | 0 | 1 | 1 |
| Withdrew: Withdrawal by subject | 2 | 2 | 4 |
To demonstrate the efficacy of durvalumab in combination with platinum-based chemotherapy (paclitaxel and carboplatin) followed by maintenance durvalumab or durvalumab with olaparib when compared to platinum-based chemotherapy by assessment of PFS (using investigator assessment according to Response Evaluation Criteria in Solid Tumours version 1.1 \[RECIST 1.1\]) in patients with newly diagnosed advanced or recurrent endometrial cancer
| Months | Global Cohort - SoC | Global Cohort - SoC + Durvalumab | Global Cohort - SoC + Durvalumab + Olaparib | China Cohort - SoC | China Cohort - SoC + Durvalumab | China Cohort - SoC + Durvalumab + Olaparib |
|---|---|---|---|---|---|---|
| Progression-free Survival (PFS) According to RECIST 1.1, Based on Investigator Assessments | 9.6 (9.0 to 9.9) | 10.2 (9.7 to 14.7) | 15.1 (12.6 to 20.7) | 9.7 (7.6 to 12.3) | 9.9 (8.2 to 20.6) | 9.9 (7.1 to 12.6) |
To determine the efficacy of durvalumab in combination with platinum-based chemotherapy (paclitaxel and carboplatin) followed by maintenance durvalumab or durvalumab with olaparib when compared to platinum-based chemotherapy in newly diagnosed advanced or recurrent endometrial cancer patients by assessment of OS
Results for this outcome have not been posted.
To determine the efficacy of durvalumab in combination with platinum-based chemotherapy (paclitaxel and carboplatin) followed by maintenance durvalumab or durvalumab with olaparib when compared to platinum-based chemotherapy in newly diagnosed advanced or recurrent endometrial cancer patients by assessment of PFS2
| Months | Global Cohort - SoC | Global Cohort - SoC + Durvalumab | Global Cohort - SoC + Durvalumab + Olaparib | China Cohort - SoC | China Cohort - SoC + Durvalumab | China Cohort - SoC + Durvalumab + Olaparib |
|---|---|---|---|---|---|---|
| Time From Randomisation to Second Progression or Death (PFS2) Based on Local Standard Clinical Practice | 19.1 (16.4 to 22.9) | 22.2 (18.7 to NA) | NA (NA to NA) | 24.2 (15.5 to NA) | 19.7 (15.3 to NA) | 15.3 (12.7 to NA) |
To determine the efficacy of durvalumab in combination with platinum-based chemotherapy (paclitaxel and carboplatin) followed by maintenance durvalumab or durvalumab with olaparib when compared to platinum-based chemotherapy in newly diagnosed advanced or recurrent endometrial cancer patients by assessment of ORR
| Percentage of participants | Global Cohort - SoC | Global Cohort - SoC + Durvalumab | Global Cohort - SoC + Durvalumab + Olaparib | China Cohort - SoC | China Cohort - SoC + Durvalumab | China Cohort - SoC + Durvalumab + Olaparib |
|---|---|---|---|---|---|---|
| Objective Response Rate (ORR) Based on Investigator Assessment | 55.1 | 61.9 | 63.6 | 59.5 | 59.4 | 45.5 |
To determine the efficacy of durvalumab in combination with platinum-based chemotherapy (paclitaxel and carboplatin) followed by maintenance durvalumab or durvalumab with olaparib when compared to platinum-based chemotherapy in newly diagnosed advanced or recurrent endometrial cancer patients by assessment of DoR
| Months | Global Cohort - SoC | Global Cohort - SoC + Durvalumab | Global Cohort - SoC + Durvalumab + Olaparib |
|---|---|---|---|
| Duration of Response (DoR) Based on Investigator Assessment | 7.7 (5.1 to 13.5) | 13.1 (6.0 to NA) | 21.3 (8.1 to 29.9) |
To determine the efficacy of durvalumab in combination with platinum-based chemotherapy (paclitaxel and carboplatin) followed by maintenance durvalumab or durvalumab with olaparib when compared to platinum-based chemotherapy in newly diagnosed advanced or recurrent endometrial cancer patients by assessment of TFST
Results for this outcome have not been posted.
To determine the efficacy of durvalumab in combination with platinum-based chemotherapy (paclitaxel and carboplatin) followed by maintenance durvalumab or durvalumab with olaparib when compared to platinum-based chemotherapy in newly diagnosed advanced or recurrent endometrial cancer patients by assessment of TSST
Results for this outcome have not been posted.
To determine the efficacy of durvalumab in combination with platinum-based chemotherapy (paclitaxel and carboplatin) followed by maintenance durvalumab or durvalumab with olaparib when compared to platinum-based chemotherapy in newly diagnosed advanced or recurrent endometrial cancer patients by assessment of TDT
Results for this outcome have not been posted.
To characterise the pharmacokinetics (PK) of durvalumab and durvalumab in combination with olaparib
| μg/mL | Global Cohort - SoC + Durvalumab | Global Cohort - SoC + Durvalumab + Olaparib | China Cohort - SoC + Durvalumab | China Cohort - SoC + Durvalumab + Olaparib |
|---|---|---|---|---|
| Day 85, pre-dose (Trough concentration) | 203.133538 ± 32.6 | 196.218276 ± 31.7 | 183.414442 ± 32.7 | NA ± NA |
| Day 183, pre-dose (Trough concentration) | 265.575840 ± 39.6 | 236.315365 ± 38.0 | — | NA ± NA |
| Follow-up 3-months (Last valid dose + 3 months) | 27.977227 ± 104.4 | 14.031316 ± 206.8 | 33.310921 ± 43.0 | 11.252155 ± 1429.7 |
To characterise the immunogenicity of durvalumab and durvalumab in combination with olaparib
| Number of participants | Global Cohort - SoC + Durvalumab | Global Cohort - SoC + Durvalumab + Olaparib | China Cohort - SoC + Durvalumab | China Cohort - SoC + Durvalumab + Olaparib |
|---|---|---|---|---|
| ADA-positive at any visit (ADA prevalence) | 8 | 9 | 0 | 1 |
| Treatment-emergent ADA-positive (ADA incidence) | 2 | 0 | 0 | 0 |
| Treatment-boosted ADA | 0 | 0 | 0 | 0 |
| Treatment-induced ADA (positive post-baseline only) | 2 | 0 | 0 | 0 |
| ADA positive at baseline only | 6 | 9 | 0 | 1 |
| ADA positive post-baseline and positive at baseline | 0 | 0 | 0 | 0 |
| Persistently positive | 2 | 0 | 0 | 0 |
| Transiently positive | 0 | 0 | 0 | 0 |
| Neutralising antibody positive at any visit | 1 | 0 | 0 | 0 |
To determine effects on symptoms, functioning, and overall health related quality of life (HRQoL) of durvalumab in combination with platinum-based chemotherapy (paclitaxel and carboplatin) followed by maintenance durvalumab or durvalumab with olaparib when compared to platinum-based chemotherapy alone in newly diagnosed advanced or recurrent endometrial cancer patients. The physical functioning score is a score from 0 to 100. Higher scores on the physical functioning score indicate better health status/function.
| Score on a scale | Global Cohort - SoC | Global Cohort - SoC + Durvalumab | Global Cohort - SoC + Durvalumab + Olaparib |
|---|---|---|---|
| Change From Baseline in Physical Functioning Score of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire for Cancer Patients 30 (EORTC QLQ-C30) | -5.3 ± 1.03 | -3.6 ± 1.02 | -5.9 ± 0.98 |
To determine effects on symptoms, functioning, and overall HRQoL of durvalumab in combination with platinum-based chemotherapy (paclitaxel and carboplatin) followed by maintenance durvalumab or durvalumab with olaparib when compared to platinum-based chemotherapy alone in newly diagnosed advanced or recurrent endometrial cancer patients. The global health status/quality of life (QoL) is a score from 0 to 100. Higher scores on the global health status/QoL indicate better health status/function.
| Score on a scale | Global Cohort - SoC | Global Cohort - SoC + Durvalumab | Global Cohort - SoC + Durvalumab + Olaparib |
|---|---|---|---|
| Change From Baseline in Global Health Status/QoL Score of the EORTC QLQ-C30 | -2.8 ± 0.93 | -2.7 ± 0.92 | -3.6 ± 0.88 |
Collected over Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Global Cohort - SoC | 82/241 (34%) | 73/236 (30.9%) | 233/236 (98.7%) |
| Global Cohort - SoC + Durvalumab | 65/238 (27.3%) | 73/235 (31.1%) | 228/235 (97%) |
| Global Cohort - SoC + Durvalumab + Olaparib | 52/239 (21.8%) | 85/238 (35.7%) | 236/238 (99.2%) |
| China Cohort - SoC | 12/44 (27.3%) | 14/44 (31.8%) | 44/44 (100%) |
| China Cohort - SoC + Durvalumab | 11/43 (25.6%) | 8/41 (19.5%) | 41/41 (100%) |
| China Cohort - SoC + Durvalumab + Olaparib | 14/42 (33.3%) | 19/41 (46.3%) | 39/41 (95.1%) |
| Event | Global Cohort - SoC | Global Cohort - SoC + Durvalumab | Global Cohort - SoC + Durvalumab + Olaparib | China Cohort - SoC | China Cohort - SoC + Durvalumab | China Cohort - SoC + Durvalumab + Olaparib |
|---|---|---|---|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 10/236 | 1/235 | 16/238 | 1/44 | 1/41 | 4/41 |
| Alanine aminotransferase increasedInvestigations | 0/236 | 0/235 | 0/238 | 1/44 | 2/41 | 0/41 |
| Aspartate aminotransferase increasedInvestigations | 0/236 | 0/235 | 0/238 | 1/44 | 0/41 | 2/41 |
| PyrexiaGeneral disorders | 1/236 | 1/235 | 3/238 | 0/44 | 1/41 | 2/41 |
| Platelet count decreasedInvestigations | 0/236 | 1/235 | 1/238 | 2/44 | 0/41 | 0/41 |
| DizzinessNervous system disorders | 1/236 | 1/235 | 0/238 | 2/44 | 1/41 | 0/41 |
| Febrile neutropeniaBlood and lymphatic system disorders | 8/236 | 4/235 | 7/238 | 2/44 | 0/41 | 0/41 |
| Urinary tract infectionInfections and infestations | 5/236 | 2/235 | 6/238 | 0/44 | 0/41 | 0/41 |
| MyelosuppressionBlood and lymphatic system disorders | 1/236 | 0/235 | 2/238 | 1/44 | 0/41 | 1/41 |
| SepsisInfections and infestations | 3/236 | 2/235 | 4/238 | 0/44 | 1/41 | 0/41 |
| Event | Global Cohort - SoC | Global Cohort - SoC + Durvalumab | Global Cohort - SoC + Durvalumab + Olaparib | China Cohort - SoC | China Cohort - SoC + Durvalumab | China Cohort - SoC + Durvalumab + Olaparib |
|---|---|---|---|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 121/236 | 111/235 | 141/238 | 36/44 | 28/41 | 34/41 |
| White blood cell count decreasedInvestigations | 40/236 | 29/235 | 38/238 | 32/44 | 30/41 | 31/41 |
| Neutrophil count decreasedInvestigations | 60/236 | 43/235 | 50/238 | 30/44 | 30/41 | 29/41 |
| AlopeciaSkin and subcutaneous tissue disorders | 118/236 | 118/235 | 121/238 | 29/44 | 20/41 | 26/41 |
| NauseaGastrointestinal disorders | 105/236 | 95/235 | 129/238 | 18/44 | 11/41 | 18/41 |
| Platelet count decreasedInvestigations | 37/236 | 36/235 | 39/238 | 21/44 | 13/41 | 15/41 |
| HypoaesthesiaNervous system disorders | 12/236 | 9/235 | 15/238 | 16/44 | 7/41 | 18/41 |
| VomitingGastrointestinal disorders | 42/236 | 46/235 | 61/238 | 11/44 | 11/41 | 18/41 |
| FatigueGeneral disorders | 87/236 | 82/235 | 93/238 | 4/44 | 2/41 | 6/41 |
| Alanine aminotransferase increasedInvestigations | 18/236 | 30/235 | 30/238 | 17/44 | 16/41 | 11/41 |
Global cohort: 241 SoC, 238 SoC + Durvalumab, 239 SoC + Durvalumab + Olaparib China cohort: 44 SoC, 43 SoC + Durvalumab, 42 SoC + Durvalumab + Olaparib There were 42 patients included in both Global and China cohorts (15 SOC, 14 SoC + Durvalumab, 13 SoC + Durvalumab + Olaparib).
| Age, Continuous(Years) | SoC (Global Cohort & China Cohort) | SoC + Durvalumab (Global Cohort & China Cohort) | SoC + Durvalumab + Olaparib (Global Cohort & China Cohort) | Total |
|---|---|---|---|---|
| Global cohort | 62.1 ± 10.36 | 63.3 ± 9.82 | 62.4 ± 9.90 | 62.6 ± 10.03 |
| China cohort | 58.3 ± 8.73 | 57.6 ± 10.57 | 59.3 ± 8.41 | 58.4 ± 9.24 |
| Age, Customized(Participants) | SoC (Global Cohort & China Cohort) | SoC + Durvalumab (Global Cohort & China Cohort) | SoC + Durvalumab + Olaparib (Global Cohort & China Cohort) | Total |
|---|---|---|---|---|
| Global cohort — <65 years | 124 | 122 | 135 | 381 |
| Global cohort — >=65 years | 117 | 116 | 104 | 337 |
| China cohort — <65 years | 35 | 30 | 30 | 95 |
| China cohort — >=65 years | 9 | 13 | 12 | 34 |
| Sex/Gender, Customized(Participants) | SoC (Global Cohort & China Cohort) | SoC + Durvalumab (Global Cohort & China Cohort) | SoC + Durvalumab + Olaparib (Global Cohort & China Cohort) | Total |
|---|---|---|---|---|
| Global cohort — Female | 241 | 238 | 239 | 718 |
| China cohort — Female | 44 | 43 | 42 | 129 |
| Ethnicity (NIH/OMB)(Participants) | SoC (Global Cohort & China Cohort) | SoC + Durvalumab (Global Cohort & China Cohort) | SoC + Durvalumab + Olaparib (Global Cohort & China Cohort) | Total |
|---|---|---|---|---|
| Global cohort — Hispanic or Latino | 20 | 28 | 32 | 80 |
| Global cohort — Not Hispanic or Latino | 218 | 208 | 206 | 632 |
| Global cohort — Unknown or Not Reported | 3 | 2 | 1 | 6 |
| China cohort — Hispanic or Latino | 0 | 0 | 0 | 0 |
| China cohort — Not Hispanic or Latino | 44 | 43 | 42 | 129 |
| China cohort — Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | SoC (Global Cohort & China Cohort) | SoC + Durvalumab (Global Cohort & China Cohort) | SoC + Durvalumab + Olaparib (Global Cohort & China Cohort) | Total |
|---|---|---|---|---|
| Global cohort — White | 143 | 136 | 133 | 412 |
| Global cohort — Asian | 73 | 72 | 70 | 215 |
| Global cohort — Black or African American | 10 | 11 | 14 | 35 |
| Global cohort — Other | 10 | 8 | 12 | 30 |
| Global cohort — American Indian or Alaska Native | 0 | 6 | 6 | 12 |
| Global cohort — Native Hawaiian or Other Pacific Islander | 2 | 0 | 1 | 3 |
| Global cohort — Not reported | 3 | 5 | 3 | 11 |
| China cohort — White | 0 | 0 | 0 | 0 |
| China cohort — Asian | 44 | 43 | 42 | 129 |
| China cohort — Black or African American | 0 | 0 | 0 | 0 |
| China cohort — Other | 0 | 0 | 0 | 0 |
| China cohort — American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| China cohort — Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| China cohort — Not reported | 0 | 0 | 0 | 0 |
Showing the first 100 of 201 sites across 22 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
Supporting information: Study protocol, Statistical analysis plan
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
Access criteria: When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com
Ran from May 2020 to primary completion in Jul 2024, 50 months.
Results were first posted in Dec 2025, 1 year 5 months after primary completion.
Of 44 phase 3 interventional studies under Endometrial Neoplasms, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 45 and three quarters within 126. This study's 50 months is close to that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Olaparib · Durvalumab